Cell Biology and Toxicology Клеточная биология
Multimethod screening identifies baicalein as a direct IDO1 inhibitor that restores tryptophan metabolism and repairs intestinal barrier in ulcerative colitis
Аннотация
Emerging evidence implicates dysregulated metabolism of tryptophan (Trp) in ulcerative colitis (UC) and associated mood comorbidities via the indoleamine 2,3-dioxygenase 1 (IDO1)-kynurenine (Kyn)-quinolinic acid axis. Here, we identified baicalein, a natural direct IDO1 inhibitor, as a compound that concurrently resolved UC and depression-like behaviors. Using DSS-induced murine UC and intestinal organoid models, we screened bioactive fractions of the Huangqin Decoction using an organoid-based activity guidance. Ligand fishing, biotin pull-down, cellular thermal shift assay, drug affinity responsive target stability, and molecular docking were performed to validate baicalein as the direct effector. Metabolomics, 16S rRNA sequencing, and behavioral assays demonstrated baicalein’s specific binding to IDO1, restoration of the Trp-Kyn balance, normalization of colonic and cerebral quinolinic acid levels, repair of tight junctions (ZO-1, Occludin, and Claudin-5), prevention of bacterial translocation, and alterations in the gut microbiota and bile acid profiles, equivalent to those of 1-MT, a known IDO1 inhibitor. Thus, baicalein is a novel IDO1 inhibitor that modulates Trp metabolism and may contribute to the improvement of UC-associated depression-like behaviors. It may have potential as a naturally derived candidate for IDO1-targeted therapy in UC. Graphical abstract